Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.
Amino Acids
/ administration & dosage
Animals
Bridged Bicyclo Compounds, Heterocyclic
/ administration & dosage
Dose-Response Relationship, Drug
Excitatory Amino Acid Agonists
/ administration & dosage
Fluorobenzenes
/ administration & dosage
Hallucinogens
/ pharmacology
Locomotion
/ drug effects
Male
Mice
Mice, Inbred C57BL
Phenethylamines
/ pharmacology
Piperidines
/ administration & dosage
Psychotropic Drugs
/ pharmacology
Receptor, Serotonin, 5-HT2A
/ metabolism
Receptors, Metabotropic Glutamate
/ agonists
Serotonin 5-HT2 Receptor Agonists
/ pharmacology
Serotonin Antagonists
/ pharmacology
5-HT2A
Hallucinogen
Head twitch
Metabotropic glutamate receptor
Serotonin
mGlu2/3
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
27
02
2018
accepted:
08
11
2018
pubmed:
19
11
2018
medline:
26
4
2019
entrez:
19
11
2018
Statut:
ppublish
Résumé
There is evidence that mGlu2/3 receptors regulate 5-HT We first conducted a dose response of 25CN-NBOH (0.1, 0.3, 1, 3, or 10 mg/kg) to confirm the effects on head-twitch response (HTR) and then blockade studies with either the M100907 (0.1 mg/kg) or SB242084 (0.1, 0.3, or 1 mg/kg) to determine the contribution of 5-HT2A and 5-HT2C to 25CN-NBOH-induced HTR, respectively. To determine whether an mGlu2/3 agonist could block 25CN-NBOH-induced HTR, mice were pretreated with vehicle or LY379268 (0.1, 1, or 10 mg/kg) prior to 25CN-NBOH, and HTR was assessed. The effects of chronic LY379268 on 5-HT2A agonist-induced HTR were evaluated by treating mice with either vehicle or LY379268 (10 mg/kg) for 21 days and measuring 25CN-NBOH-induced HTR 48 h after the final LY379268 treatment. The following day (72 h after the final LY379268 treatment), the ability of acute LY379268 to block PCP-induced locomotor activity was assessed. 25CN-NBOH dose-dependently increased the HTR, a 5-HT These data are consistent with a functional interaction between mGlu2/3 and 5-HT
Sections du résumé
BACKGROUND
BACKGROUND
There is evidence that mGlu2/3 receptors regulate 5-HT
METHODS
METHODS
We first conducted a dose response of 25CN-NBOH (0.1, 0.3, 1, 3, or 10 mg/kg) to confirm the effects on head-twitch response (HTR) and then blockade studies with either the M100907 (0.1 mg/kg) or SB242084 (0.1, 0.3, or 1 mg/kg) to determine the contribution of 5-HT2A and 5-HT2C to 25CN-NBOH-induced HTR, respectively. To determine whether an mGlu2/3 agonist could block 25CN-NBOH-induced HTR, mice were pretreated with vehicle or LY379268 (0.1, 1, or 10 mg/kg) prior to 25CN-NBOH, and HTR was assessed. The effects of chronic LY379268 on 5-HT2A agonist-induced HTR were evaluated by treating mice with either vehicle or LY379268 (10 mg/kg) for 21 days and measuring 25CN-NBOH-induced HTR 48 h after the final LY379268 treatment. The following day (72 h after the final LY379268 treatment), the ability of acute LY379268 to block PCP-induced locomotor activity was assessed.
RESULTS
RESULTS
25CN-NBOH dose-dependently increased the HTR, a 5-HT
CONCLUSIONS
CONCLUSIONS
These data are consistent with a functional interaction between mGlu2/3 and 5-HT
Identifiants
pubmed: 30448990
doi: 10.1007/s00213-018-5118-y
pii: 10.1007/s00213-018-5118-y
pmc: PMC6778591
mid: NIHMS997445
doi:
Substances chimiques
Amino Acids
0
Bridged Bicyclo Compounds, Heterocyclic
0
Excitatory Amino Acid Agonists
0
Fluorobenzenes
0
Hallucinogens
0
LY 379268
0
Phenethylamines
0
Piperidines
0
Psychotropic Drugs
0
Receptor, Serotonin, 5-HT2A
0
Receptors, Metabotropic Glutamate
0
Serotonin 5-HT2 Receptor Agonists
0
Serotonin Antagonists
0
metabotropic glutamate receptor 2
0
metabotropic glutamate receptor 3
0
phenethylamine
327C7L2BXQ
volinanserin
EW71EE171J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
821-830Subventions
Organisme : National Institute on Drug Abuse
ID : R01 DA002925
Organisme : National Institute on Drug Abuse
ID : R01 DA041336
Organisme : NIDA NIH HHS
ID : R01 DA041336
Pays : United States
Organisme : NIMH NIH HHS
ID : K01 MH100644
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA002925
Pays : United States
Organisme : National Institute of Mental Health
ID : K01 MH100644
Organisme : U.S. Department of Veterans Affairs
ID : VISN 22 MIRECC
Références
Brain Res. 1999 Apr 17;825(1-2):161-71
pubmed: 10216183
J Pharmacol Exp Ther. 1999 Oct;291(1):161-70
pubmed: 10490900
J Pharmacol Exp Ther. 2000 Jan;292(1):76-87
pubmed: 10604933
J Pharmacol Exp Ther. 2000 Sep;294(3):800-9
pubmed: 10945827
Neuropsychopharmacology. 2000 Nov;23(5):569-76
pubmed: 11027922
J Neurosci. 2000 Dec 1;20(23):8846-52
pubmed: 11102493
Neuropharmacology. 2001 Jun;40(7):847-55
pubmed: 11378155
J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8
pubmed: 11504829
J Pharmacol Exp Ther. 2001 Oct;299(1):12-20
pubmed: 11561058
Pharmacol Biochem Behav. 2002 Sep;73(2):327-32
pubmed: 12117586
Neuropsychopharmacology. 2003 Jan;28(1):45-52
pubmed: 12496939
Neuroscience. 2003;117(3):697-706
pubmed: 12617973
Psychopharmacology (Berl). 2004 Mar;172(2):233-40
pubmed: 14598016
Pharmacol Ther. 2004 Feb;101(2):131-81
pubmed: 14761703
Neuropharmacology. 2004 Mar;46(3):331-9
pubmed: 14975688
Neuropsychopharmacology. 2005 Jul;30(7):1324-33
pubmed: 15688082
Eur J Pharmacol. 2005 May 23;516(1):28-33
pubmed: 15913602
J Pharmacol Exp Ther. 2005 Dec;315(3):1181-7
pubmed: 16123306
Neurosci Lett. 2006 Aug 7;403(3):256-60
pubmed: 16759803
Neuron. 2007 Feb 1;53(3):439-52
pubmed: 17270739
Mol Pharmacol. 2007 Aug;72(2):477-84
pubmed: 17526600
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):62-71
pubmed: 17728034
Nat Med. 2007 Sep;13(9):1102-7
pubmed: 17767166
Neuropsychopharmacology. 2008 Aug;33(9):2206-16
pubmed: 17957214
Nature. 2008 Mar 6;452(7183):93-7
pubmed: 18297054
Neuropsychopharmacology. 2009 Jan;34(1):248-9
pubmed: 19079073
Mol Pharmacol. 2009 Apr;75(4):991-1003
pubmed: 19164443
Neuropsychopharmacology. 2009 Jul;34(8):1958-67
pubmed: 19322172
Mol Pharmacol. 2009 Aug;76(2):379-87
pubmed: 19439499
J Pharmacol Exp Ther. 2010 Dec;335(3):728-34
pubmed: 20858706
Neurosci Lett. 2011 Apr 15;493(3):76-9
pubmed: 21276828
Pharmacol Biochem Behav. 2011 Jul;99(1):52-8
pubmed: 21504759
J Clin Psychopharmacol. 2011 Jun;31(3):349-55
pubmed: 21508856
Psychopharmacology (Berl). 2012 Jan;219(2):387-400
pubmed: 21863235
Cell. 2011 Nov 23;147(5):1011-23
pubmed: 22118459
Neuropharmacology. 2012 Jun;62(7):2184-91
pubmed: 22300836
Drug Test Anal. 2012 Jul-Aug;4(7-8):556-76
pubmed: 22517680
Pharmacogenomics. 2012 Aug;13(11):1227-37
pubmed: 22920393
J Biol Chem. 2012 Dec 28;287(53):44301-19
pubmed: 23129762
Neurosci Lett. 2013 Mar 1;536:69-73
pubmed: 23333599
Neuropharmacology. 2013 Jul;70:218-27
pubmed: 23376711
Psychopharmacology (Berl). 2013 Jun;227(4):727-39
pubmed: 23407781
Neuropharmacology. 2013 Jul;70:296-305
pubmed: 23466331
Mol Pharmacol. 2013 Jun;83(6):1166-75
pubmed: 23508685
Behav Brain Res. 2013 Nov 1;256:298-304
pubmed: 23948211
Neuropharmacology. 2014 Feb;77:200-7
pubmed: 24012658
ACS Chem Neurosci. 2014 Mar 19;5(3):243-9
pubmed: 24397362
Int J Neuropsychopharmacol. 2014 Aug;17(8):1269-82
pubmed: 24650558
Psychopharmacology (Berl). 2015 Jan;232(1):275-84
pubmed: 24985890
Behav Brain Res. 2015 Jan 15;277:99-120
pubmed: 25036425
Psychopharmacology (Berl). 2015 Mar;232(6):1039-47
pubmed: 25224567
Psychopharmacology (Berl). 1989;99(1):64-9
pubmed: 2550988
BMC Psychiatry. 2014 Dec 10;14:351
pubmed: 25539791
ACS Chem Neurosci. 2015 Jul 15;6(7):1165-75
pubmed: 25547199
J Pers Med. 2016 Feb 05;6(1):null
pubmed: 26861400
Neuropharmacology. 2016 Aug;107:364-375
pubmed: 27020041
J Pharmacol Exp Ther. 2017 Jun;361(3):441-453
pubmed: 28360333
Front Pharmacol. 2018 Feb 06;9:17
pubmed: 29467649
Neuropharmacology. 2018 Nov;142:231-239
pubmed: 29499272
Front Pharmacol. 2018 Mar 15;9:208
pubmed: 29599719
Psychopharmacology (Berl). 1995 May;119(1):9-14
pubmed: 7675955
Science. 1998 Aug 28;281(5381):1349-52
pubmed: 9721099